



Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA

La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company's highly selective and orally active dual PI3K delta/gamma inhibitor, has been selected for oral and poster presentations at the upcoming 10th Annual T-Cell Lymphoma Forum, to be held February 1-3, 2018, at Hilton La Jolla Torrey Pines in La Jolla, CA, USA. Clinical data highlights as well as details of the presentations are outlined below:

Clinical Data Highlights:

- ***Tenalisib (RP6530) updated data from ongoing Phase I/Ib study:***
Demonstrated highly promising single-agent clinical activity with acceptable safety in relapsed/refractory T-cell Lymphoma.
 - R/R Peripheral T-cell Lymphoma (R/R PTCL) objective response rate **(ORR) = 50%**
 - R/R Cutaneous T-cell Lymphoma (R/R CTCL) objective response rate **(ORR) = 44%**

Details of the oral presentation:

- **Oral Presentation Title: RP6530, a dual PI3K δ/γ inhibitor: Interim results of a Phase I/Ib Study in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma**
 - **Session:** 6
 - **Date:** Friday, February 2, 2018
 - **Location:** Hilton La Jolla Torrey Pines, La Jolla, CA
 - **Presenter:** Bradley Haverkos, MD, MPH, University of Colorado School of Medicine, Denver, CO

Details of the poster presentation:

- **Poster Title: Results of Ongoing Phase 1/1b study of RP6530, a dual PI3K δ/γ inhibitor in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma**
 - **Date and Time:** Friday, February 2, 2018; 6:00 PM – 8:00 PM US PST
 - **Location:** Ballroom Foyer, Hilton La Jolla Torrey Pines, La Jolla, CA

- **Presenter:** Auris Huen, MD, University of Texas MD Anderson Cancer Center, Houston, TX

About Tenalisib (RP6530):

Tenalisib (RP6530) is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies. Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of tumor microenvironment at clinically achievable concentrations. In preclinical studies, RP6530 reprograms macrophages from an immunosuppressive M2-like phenotype (pro-tumor) to an inflammatory M1-like state (anti-tumor), which can potentially enhance the activity of checkpoint inhibitors or overcome resistance to these drugs. Tenalisib obtained US FDA Fast Track and Orphan-Drug Designations for treatment of peripheral T-cell lymphoma (PTCL).

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website, www.rhizen.com.

Contact: Kumar V. Penmetsa, Ph.D.
Executive Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone: +1-267-207-5707
Email: kvp@rhizen.com